Upstream Bio Inc
NASDAQ:UPB

Watchlist Manager
Upstream Bio Inc Logo
Upstream Bio Inc
NASDAQ:UPB
Watchlist
Price: 29.48 USD -2.61% Market Closed
Market Cap: 1.6B USD

Operating Margin
Upstream Bio Inc

-5 020.1%
Current
-3 897%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 020.1%
=
Operating Profit
-140.5m
/
Revenue
2.8m

Operating Margin Across Competitors

No Stocks Found

Upstream Bio Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The firm has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).

UPB Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 020.1%
=
Operating Profit
-140.5m
/
Revenue
2.8m
What is the Operating Margin of Upstream Bio Inc?

Based on Upstream Bio Inc's most recent financial statements, the company has Operating Margin of -5 020.1%.

Back to Top